Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Insider and Institutional Ownership
44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 9.1% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Tvardi Therapeutics and Incannex Healthcare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
| Incannex Healthcare | 2 | 0 | 1 | 0 | 1.67 |
Tvardi Therapeutics presently has a consensus price target of $9.40, suggesting a potential upside of 893.55%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 934.48%. Given Incannex Healthcare’s higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Tvardi Therapeutics.
Valuation & Earnings
This table compares Tvardi Therapeutics and Incannex Healthcare”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tvardi Therapeutics | $7.14 million | 1.77 | -$18.21 million | ($2.68) | -0.35 |
| Incannex Healthcare | $90,000.00 | 242.63 | -$19.30 million | ($1.24) | -1.40 |
Tvardi Therapeutics has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tvardi Therapeutics and Incannex Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -179.87% | -107.78% |
| Incannex Healthcare | N/A | -20.27% | -19.15% |
Risk & Volatility
Tvardi Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7, meaning that its stock price is 600% more volatile than the S&P 500.
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.
About Incannex Healthcare
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments. The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
